- Home
- WSO vs BBIO Comparison
WSO vs BBIO Comparison
Compare WSO & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WSO | BBIO |
|---|---|---|
| Founded | 1945 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5B | 15.3B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | WSO | BBIO |
|---|---|---|
| Price | $406.27 | $66.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 23 |
| Target Price | ★ $418.33 | $82.26 |
| AVG Volume (30 Days) | 393.6K | ★ 3.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $5.49 | $85.55 |
| Revenue Next Year | $5.79 | $71.10 |
| P/E Ratio | $34.24 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $323.05 | $28.33 |
| 52 Week High | $533.07 | $84.94 |
Technical Indicators
Market Signals| Indicator | WSO | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.01 | 41.14 |
| Support Level | $400.37 | $61.54 |
| Resistance Level | $430.44 | $68.71 |
| Average True Range (ATR) | 15.00 | 3.77 |
| MACD | -2.75 | -0.51 |
| Stochastic Oscillator | 28.21 | 18.72 |
Price Performance
Historical ComparisonAbout WSO Watsco Inc.
Watsco is the largest heating, ventilation, air conditioning, and refrigeration products distributor in North America. The company primarily operates in the United States (90% of revenue), with significant exposure in the Sun Belt states. Watsco also has operations in Canada (5% of sales) and Latin America (5% of sales). The company's customer base consists of more than 125,000 contractors that serve the replacement and new construction HVACR markets for residential and light commercial applications.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.